Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy

ConditionsPrimary Lung Cancer Non Small Cell Lung Cancer Small Cell Lung Cancer

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

About this trial

A randomized controlled trial to assess the impact of prophylactic proton pump inhibitor use to improve esophagitis in lung cancer patients undergoing radiation. Patients will be randomized into a standard of care arm or the prophylactic proton pump (daily) arm.

Eligibility criteria

Qualifiers

Age 18 years or older

Willing to provide informed consent

Eastern Cooperative Oncology Group (ECOG) performance status 0-3

Life expectancy of at least 3 months

Disqualifiers

• Serious medical comorbidities precluding radiotherapy

Use of PPI within 3 months prior to enrollment

Allergy to PPI

Odynophagia (painful swallowing) prior to enrollment

Trial design

Treatments tested in this trial

Experimental (Health Canada Approved Proton Pump Inhibitors)

Treatment groups

58 Participants

are divided into 2 treatment groups

Sponsors and collaborators

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Lead sponsor

Source ClinicalTrials.gov